AFFiRiS AG: Interim Analysis Of Clinical Phase I Data Triggered Decision To Move Alzheimer’s Vaccine Candidate AD02 Into Clinical Phase II Testing
Posted by: DrugsNews on: 20 Nov, 2009
AFFiRiS AG: Interim Analysis Of Clinical Phase I Data Triggered Decision To Move Alzheimer’s Vaccine Candidate AD02 Into Clinical Phase II Testing
AFFiRiS AG will focus its Alzheimer’s vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02.
Read more about AFFiRiS AG: Interim Analysis Of Clinical Phase I Data Triggered Decision To Move Alzheimer’s Vaccine Candidate AD02 Into Clinical Phase II Testing
| Indian Pharmacy! Looking for Generic Medications? Quality Drugs at affordable prices! Reliable Indian Pharmacy www.IndianPharmacy.org |
#1 Canadian Pharmacy Online! The Lowest Prices from Canadian Drugstore! Various payments, secure shopping, worldwide shipping! www.CanadianPharmacyLtd.org |
What are the Drugs-Review websites?
The Drugs-Review websites are NOT but will be your number one stop for all the latest news, comment and pharmaceutical industry information.
Related posts:
- Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-Based Cancer Vaccine Candidate, CDX-1307
- Intercell: Phase I data for Pneumococcus vaccine candidate
- Novavax Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
